2020-12-02
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read the full press release: https://www.camurus.com/
2019-08-26
Australia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical B…
Read more2019-08-07
ISEC has launched three new products for better and safer surveillance of radioactive environments.
Read more2019-07-23
Camurus’ partner Braeburn have received a positive outcome in the US court proceedings which were initiated in April…
Read more2019-06-20
The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-mon…
Read more2019-06-17
Starting June 2019, all Sandberg Development's office and production facilities will be cleaned and washed with DIRO…
Read more